Haemonetics (HAE) EBIT Margin (2009 - 2026)

Haemonetics' EBIT Margin history runs 18 years deep, the most recent figure standing at 6.65% for Q1 2026.

• On a quarterly basis, EBIT Margin fell 2823.0% year-over-year to 6.65% in Q1 2026; TTM through Mar 2026 was 11.75%, a 455.0% decrease from a year earlier, with the FY2026 full-year figure at 11.75%, down 455.0% from the prior year.
• EBIT Margin eased to 6.65% in Q1 2026 per HAE's latest filing, from 19.88% in the prior quarter.
• Across five years, EBIT Margin topped out at 21.58% in Q1 2025 and bottomed at 6.65% in Q1 2026.
• The 5-year median for EBIT Margin is 13.95% (2022), against an average of 13.23%.
• Across the five-year window, EBIT Margin soared 1665 bps in 2022 and sank 2823 bps in 2026, its largest moves.
• Year by year, EBIT Margin stood at 14.18% in 2022, then decreased by 4 bps to 13.67% in 2023, then gained by 24 bps to 16.94% in 2024, then grew by 17 bps to 19.88% in 2025, then plunged by 133 bps to 6.65% in 2026.
• Per Business Quant, the three latest HAE EBIT Margin figures stand at 6.65% (Q1 2026), 19.88% (Q4 2025), and 17.87% (Q3 2025).